Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05496868 · ClinicalTrials.gov registry record · Phase 2
Add-on Reparixin in Adult Patients With ARDS
A Phase 2 study, sponsored by Dompé Farmaceutici S.p.A.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT05496868 is a Phase 2 study that has completed, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 66 participants.
The verdict
NCT05496868, a Phase 2 study, has completed, sponsored by Dompé Farmaceutici S.p.A.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Interventions
- OTHER Matching Placebo
- DRUG Reparixin 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2025-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05496868
The ClinicalTrials.gov registry entry for NCT05496868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dompé Farmaceutici S.p.A, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05496868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05496868 about?
NCT05496868 is a clinical study titled "Add-on Reparixin in Adult Patients With ARDS". Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixi...
What is the current status of trial NCT05496868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2022-12-06. Estimated completion is 2025-04-18.
What interventions are being tested in trial NCT05496868?
The interventions under investigation include: Matching Placebo (OTHER), Reparixin 600mg (DRUG).
Who is sponsoring clinical trial NCT05496868?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.